End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.46 CNY | -0.84% |
|
+4.11% | -2.31% |
Dec. 05 | Hualan Biological Engineering Gets Plasma Donor License for Wushan Plasma Station | MT |
Nov. 22 | Hualan Biological Engineering's Unit Gets Certificate for Cancer Drug's Registration | MT |
Capitalization | 30.1B 4.12B 3.98B 3.76B 3.32B 5.89B 357B 6.54B 44.75B 16.61B 149B 15.44B 15.13B 627B | P/E ratio 2024 * |
22.2x | P/E ratio 2025 * | 17.6x |
---|---|---|---|---|---|
Enterprise value | 28.11B 3.85B 3.72B 3.51B 3.1B 5.5B 334B 6.11B 41.79B 15.51B 139B 14.42B 14.13B 586B | EV / Sales 2024 * |
5.47x | EV / Sales 2025 * | 4.71x |
Free-Float |
52.69% | Yield 2024 * |
1.73% | Yield 2025 * | 1.98% |
1 day | -0.84% | ||
1 week | +4.11% | ||
Current month | +4.11% | ||
1 month | +4.24% | ||
3 months | -6.21% | ||
6 months | +4.05% | ||
Current year | -2.31% |







Director | Title | Age | Since |
---|---|---|---|
Bei Fan
CEO | Chief Executive Officer | 53 | 2022-04-27 |
Jun Min Xie
DFI | Director of Finance/CFO | 57 | 2013-04-23 |
Xiao Wei Ma
CTO | Chief Tech/Sci/R&D Officer | 57 | 2013-04-23 |
Manager | Title | Age | Since |
---|---|---|---|
Kang An
CHM | Chairman | 76 | 2007-04-11 |
Bei Fan
BRD | Director/Board Member | 53 | 2013-03-31 |
Bao Xian Zhang
BRD | Director/Board Member | 54 | 2022-04-27 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.73% | 0 M€ | -2.96% | - | |
0.68% | 0 M€ | -20.08% | - |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-0.84% | +4.11% | -13.28% | -37.30% | 4.16B | ||
-1.07% | -5.89% | -12.34% | +4.45% | 82.2B | ||
+3.89% | +17.40% | +44.05% | +51.29% | 55.45B | ||
-0.94% | +1.94% | +102.18% | +116.90% | 37.4B | ||
-2.21% | -2.18% | -42.16% | -35.04% | 20.77B | ||
-3.57% | +7.23% | +392.19% | +798.22% | 14.4B | ||
+0.35% | +0.52% | +75.29% | +140.63% | 13.51B | ||
-2.88% | -10.51% | +15.04% | -0.64% | 13.16B | ||
+0.08% | +1.08% | -28.16% | -30.10% | 12.1B | ||
-1.84% | -2.83% | +5.42% | -36.66% | 11.67B | ||
Average | -0.90% | +0.24% | +53.82% | +97.18% | 26.48B | |
Weighted average by Cap. | -0.21% | +1.19% | +41.18% | +72.86% |
2024 * | 2025 * | |
---|---|---|
Net sales | 5.14B 703M 679M 641M 566M 1.01B 60.99B 1.12B 7.63B 2.83B 25.34B 2.63B 2.58B 107B | 6.1B 835M 807M 762M 672M 1.19B 72.47B 1.33B 9.07B 3.37B 30.11B 3.13B 3.07B 127B |
Net income | 1.36B 186M 180M 170M 150M 267M 16.17B 296M 2.02B 751M 6.72B 698M 685M 28.38B | 1.69B 231M 224M 211M 186M 331M 20.08B 368M 2.51B 933M 8.34B 867M 850M 35.24B |
Net Debt | -1.99B -272M -263M -249M -219M -390M -23.65B -433M -2.96B -1.1B -9.82B -1.02B -1B -41.49B | -1.37B -188M -182M -171M -151M -269M -16.3B -298M -2.04B -757M -6.77B -704M -690M -28.61B |
Date | Price | Change | Volume |
---|---|---|---|
25-02-11 | 16.46 ¥ | -0.84% | 8,574,127 |
25-02-10 | 16.60 ¥ | +1.90% | 11,586,160 |
25-02-07 | 16.29 ¥ | -0.06% | 10,909,890 |
25-02-06 | 16.30 ¥ | -0.49% | 9,537,435 |
End-of-day quote Shenzhen S.E., February 10, 2025
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 002007 Stock